Preview

HIV Infection and Immunosuppressive Disorders

Advanced search

CHARACTERISTICS OF LEVELS OF SERUM MARKERS OF APOPTOSIS FAS-SYSTEMS IN HIV-MONO-INFECTED PERSONS, PATIENTS WITH HIV/HCV-CO-INFECTION AND CHRONIC VIRAL HEPATITIS C

https://doi.org/10.22328/2077-9828-2019-11-4-98-102

Abstract

The purpose of the study is to investigate aspects of concentrations of serum markers of FAS-system of apoptosis in HIV-positive people including people with hepatitis C (HCV). Materials and methods: determination of concentration of soluble FAS receptor (sFas/APO-1/CD95) and Fas ligand (sFas-L) by enzyme-linked immunosorbent assay in HIV/HCV-co-infected patients (n=84), HIV-mono-infected persons (n=84), patients diagnosed with chronic viral hepatitis C (control group, n=64) and among notionally healthy population (control group, n=87). Results: higher levels of sFas in HIV-mono- and HIV/HCVco-infected patients in comparison with control groups (notionally healthy population and patients with chronic viral hepatitis C) were detected. Conclusion: definite aspects of levels of apoptosis serum markers testify higher risk of developing paraneoplastic syndromes in HIV-positive patients including HCV-co-infected patients.

About the Authors

E. A. Bazykina
Khabarovsk Research Institute of Epidemiology and Microbiology of Rospotrebnadzor
Russian Federation
Khabarovsk, Russia



V. B. Turkutyukov
Pacific State Medical University
Russian Federation
Vladivistok, Russia


O. E. Trotsenko
Khabarovsk Research Institute of Epidemiology and Microbiology of Rospotrebnadzor
Russian Federation
Khabarovsk, Russia



V. O. Kotova
Khabarovsk Research Institute of Epidemiology and Microbiology of Rospotrebnadzor
Russian Federation
Khabarovsk, Russia



L. A. Balakhontseva
Khabarovsk Research Institute of Epidemiology and Microbiology of Rospotrebnadzor
Russian Federation
Khabarovsk, Russia



References

1. Бобкова М.Р. Иммунитет и ВИЧ-инфекция. М.: Олимпия Пресс, 2006. 240 с.

2. Strasser A., Jost P.J., Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. j. immuni. 2009. Vol. 30. No. 2. Р. 180–192. DOI: 10.1016/ 2009.01.001.

3. Peptide inhibitors as novel anti-HIV therapeutics: пат. US9327009B2, МПК /B2O13/AOS1641/ Tripathi R.K., Kumar B., Ramachandran R., Tripathi J.K., Bhadauria S., Ghosh J.K; заявитель: Council of Scientific & Industrial Research; заявл. 01.03.2013; опубл. 06.09.2013. // URL: https://patentimages.storage.googleapis.com/cc/24/1e/f1623a0076d9dd/US9327009.pdf (дата доступа 10.10.2019)

4. Garg H, Joshi A. Host and Viral Factors in HIV-Mediated Bystander Apoptosis // Viruses. 2017. Vol. 9, No. 8. doi: 10.3390/v9080237.

5. Жаворонок С.В., Москалева Н.В., Тумаш О.Л., Барышников А.Ю. Перспективы клинико-лабораторного использования растворимой формы антигена CD95 // Наука и инновации. 2014. Т. 3, № 133. С. 67–72.

6. Poonia B., Pauza C.D., Salvato M.S. Role of the Fas/FasL pathway in HIV or SIV disease // Retrovirology. 2009. Vol. 86. Р. 91. DOI: 10.1186/1742-4690-6-91.

7. Москалева Н.В., Жаворонок С.В., Тумаш О.Л. Растворимая форма Fas/Apo-1-антигена в периферической крови при ВИЧ-инфекции // Актуальные вопросы инфекционной патологии: 6-й съезд инфекционистов Республики Беларусь, Витебск, 29–30 мая 2014 г. Витебск: ВГМУ, 2014. С. 129–130.

8. Hammam O., Mahmoud O., Zahran M. The Role of Fas/Fas Ligand System in the Pathogenesis of Liver Cirrhosis and Hepatocellular Carcinoma // Hepatitis Monthly. 2012. Vol. 12. No 11. e6132. doi: 10.5812/hepatmon.6132.

9. Давыдов В.Г., Бойчук С.В., Шаймарданов Р.Ш., Миннебаев М.М. Молекулярные механизмы апоптоза и некроза гепатоцитов. Особенности гибели гепатоцитов при обструктивном холестазе // Российский журнал гастроэнтерологии, гепатологии и копрологии. 2006. № 5. С. 11–19.

10. O’Connell J, Houston A, Bennett MW, O’Sullivan GC, Shanahan F. Immune privilege or inflammation Insights into the Fas ligand enigma // Nat. Med. 2001. Vol. 7. Р. 271–274.

11. Restifo N.P. Countering the «counterattack» hypothesis // Nat. Med. 2001. Vol. 7. No. 3. Р. 259. DOI: 10.1038/85357.

12. Wang X.Z., Chen X.C., Chen Y.X. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system // World J. Gastroenterol. 2003. Vol. 9. No. 12. pp. 2671–2675. DOI: 10.3748/wjg.v9.i12.2671.

13. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J., Mountz J.D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule // Science. 1994. Vol. 263. No. 5154. Р. 1759–1762.

14. Jodo S., Kobayashi S., Nakajima Y., Matsunaga T., Nakayama N., Ogura N., Kayagaki N., Okumura K., Koike T. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma // Clin. Exp. Immunol. 1998. Vol. 112. No. 2. Р. 166–171.

15. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai Т., Kitamura Y., Itoh N., Suda Т., Nagata S. Lethal effect of the antiFas antibody in mice // Nature. 1993. Vol. 364. 806 р.


Review

For citations:


Bazykina E.A., Turkutyukov V.B., Trotsenko O.E., Kotova V.O., Balakhontseva L.A. CHARACTERISTICS OF LEVELS OF SERUM MARKERS OF APOPTOSIS FAS-SYSTEMS IN HIV-MONO-INFECTED PERSONS, PATIENTS WITH HIV/HCV-CO-INFECTION AND CHRONIC VIRAL HEPATITIS C. HIV Infection and Immunosuppressive Disorders. 2019;11(4):98-102. (In Russ.) https://doi.org/10.22328/2077-9828-2019-11-4-98-102

Views: 689


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2077-9828 (Print)